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signaling and transcriptional regulation by occupying hub positions in 
the cell’s protein interaction network (PIN) (see article by Landau et al. 
in the Special Issue),10–12 we highlight the role of PAGE4 as a potentiator 
of the oncogene c‑Jun reinforcing its nuclear localization.2 Next, we 
discuss how this activity is regulated by site‑specific phosphorylation 
by Homeodomain‑Interacting Protein Kinase 1  (HIPK1), also a 
component of the cell’s stress‑response pathway.8
Finally, we discuss the biophysics of PAGE4 summarizing data that 
were obtained employing single molecule Fluorescence Resonance 
Energy Transfer  (smFRET) microscopy and multidimensional 
Nuclear Magnetic Resonance  (NMR) spectroscopy. The smFRET 
data revealed that nonphosphorylated PAGE4 interacts with c‑Jun2 
but phosphorylation attenuates this interaction.8 NMR experiments 
helped elucidate, at the single‑residue level, how site‑specific 
phosphorylation of PAGE4 leads to shifts in the conformational 
ensemble with large functional consequences.13 Finally, we point to 
alternative splicing events that can result in four different isoforms of 
the PAGE4 protein with potentially latent functions. We conclude by 
emphasizing that this endeavor serves as a paradigm for discerning 
the role of IDPs in cancer given that ~80% of the proteins dysregulated 
in the disease are IDPs.14
INTRODUCTION
In this article, in the Special Issue on Intrinsically Disordered Proteins 
and Prostate Cancer, we review the cumulative progress in research on 
Prostate‑associated Gene 4 (PAGE4), a remarkably prostate‑specific 
tumor antigen that is upregulated in prostate cancer (PCa). We begin 
with the biology of PAGE4 and review data regarding its expression at 
the mRNA as well as protein level that allude to its potentially pleotropic 
roles. These data indicate the following main points. First, while 
PAGE4 is upregulated in the developing prostate1,2 but is undetectable 
in the normal adult gland,1,3 it is aberrantly expressed in the diseased 
gland.1,3–5 Second, PAGE4 is upregulated in prostatic lesions that are 
infiltrated with inflammatory cells1,5 and are believed to represent 
precursors of frank PCa.6 Third, although mostly cytoplasmic,1,5,7,8 the 
protein is also detected in the nucleus5,8 and mitochondrial fraction.1 
Finally, PAGE4 is a stress‑response protein that is upregulated in 
response to a variety of stress factors including inflammatory stress.1
We then discuss the biochemistry of PAGE4. Biochemical 
data9 demonstrate that PAGE4 is a highly intrinsically disordered 
protein  (IDP) that lacks a rigid 3D structure and exists as a 
conformational ensemble instead. In light of the salient features of IDPs 
and the important roles they play in various cellular processes such as 
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THE BIOLOGY OF PAGE4
PAGE4 is a cancer/testis antigen (CTA)
The CTAs are a heterogeneous group of tumor antigens that are typically 
restricted to the testicular germ cells, remain silent in most somatic 
tissues, but are aberrantly expressed in several types of cancer.15,16 To 
date, more than 250 CTAs have been reported in the CT Database17,18 
that is broadly divided into two groups, namely, the CT‑X antigens 
located on the X chromosome and the non‑X CT antigens located 
on the autosomes. While the non‑X CT antigens are well conserved 
evolutionarily, the CT‑X antigens, with the possible exception of the 
MAGE family, appear to lack orthologs in lower vertebrates beyond 
primates,18,19 suggesting that these proteins have evolved relatively 
recently. The CT‑X antigens not only constitute  ~50% of all CTAs 
but also are significantly more testis‑restricted than the non‑X CT 
antigens.20 However, because of the lack of phylogenetic conservation, 
the functions of most, if not all CT‑X antigens, both in gametogenesis 
and tumorigenesis remain poorly understood.16,21,22 Furthermore, no 
activating mutations have been observed for the CTAs in any cancer thus 
far. Nonetheless, an overwhelming majority of the CTAs in general, and 
the CT‑X antigens in particular (including PAGE4), are predicted to be 
IDPs23 alluding to their potential roles in signaling and transcriptional 
regulation (see article by Landau et al. 2016 in this Issue).
PAGE4 appears to be a proto‑oncogene
The PAGE family is a subgroup of the CT‑X antigens and consists of 
five members (PAGE1‑5) that share significant sequence homology. 
Although all PAGE genes are expressed in the testes of the adult 
human, PAGE4 is the only member of this family that is expressed 
in the prostate1  (Figure  1a). Furthermore, as shown in Figure  1a, 
PAGE4 expression is remarkably prostate‑specific in human 
male yet highly dynamic.1,3 Immunohistochemistry data using a 
PAGE4‑specific antibody generated against a synthetic peptide 
corresponding to amino acids 44–60 revealed that PAGE4 is highly 
upregulated within the human prostate gland. Upregulation occurs 
both spatially and temporally in the prostatic epithelium and stromal 
cells of the fetal prostate up to 21  weeks but is undetectable by 
term (36 weeks) (Figure 1b). In contrast, PAGE4 is undetectable in the 
normal adult prostate at the level of sensitivity afforded by this specific 
antibody1,3  (Figure  1c1). However, in the malignant prostate, the 
PAGE4 protein is highly expressed in the epithelial cells in Proliferative 
Inflammatory Atrophy  (PIA) lesions1  (Figure  1c3 and 1c4) and in 
high‑grade Prostatic Intraepithelial Neoplasia (PIN) lesions,5 both of 
which are thought to be precursors of frank PCa.6 Furthermore, while 
PAGE4 protein is upregulated in frank PCa (Figure 1c5), metastatic 
PCa specimens showed no reaction to the PAGE4 antibody indicating 
the lack of PAGE4 expression in advanced disease1  (Figure  1c6). 
However, Sampson et al. reported weak expression of PAGE4 protein 
in metastatic PCa, using an in‑house PAGE4‑specific antibody to stain a 
PCa progression Tissue Microarray.5 Regardless, these data suggest that 
PAGE4 may actually function as a proto‑oncogene that is important in 
early development but is aberrantly expressed in the diseased prostate. 
Consistent with this hypothesis,  (1) PAGE4 mRNA is significantly 
upregulated when somatic cells are reprogrammed to form induced 
pluripotent stem (iPS) cells but is undetectable in the parent somatic 
cells used in reprogramming  (Figure  2a) and  (2) while knocking 
down PAGE4 expression results in cell death in vitro (Figure 2b), its 
overexpression results in a growth advantage of PCa cells (Figure 2c).9
PAGE4 is a stress‑response protein
In addition to PCa, the PAGE4 protein is also found to be expressed 
Figure 1: PAGE expression at the mRNA and protein levels. (a) Expression of mRNAs encoding PAGE1‑5 in different normal human tissue samples obtained 
from healthy donors. (b) Immunohistochemistry analysis of PAGE4 in the human fetal prostate. Samples were stained for PAGE4 at gestational weeks 12, 
21 and 36. (c) Immunohistochemistry analysis of PAGE4 in prostate cancer. (1) Negative staining in the normal prostate. (2) Intense staining shown in the 
stromal tissue in BPH. (3) Intense staining shown in cancer adjacent “normal” glands (asterisk) associated with inflammation but only moderate staining in 
the cancer cells (arrowhead). (4) High‑power view of boxed area in (3). (5) PAGE4 protein expression in organ‑confined prostate cancer. (6) Loss of PAGE4 
protein expression in metastatic prostate cancer. Asterisk: PIA lesions; arrows indicate inflammatory cells. Scale bars in all panels: 100 μm. Data presented 
are reproduced with permission from original publications by the authors.
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in benign prostatic hyperplasia (BPH).5 However, while the protein 
is not expressed in asymptomatic BPH (also referred to as histologic 
or incidental BPH), it is highly overexpressed in the symptomatic 
disease (Figure 1c2) which shares similarities with PCa at the molecular 
level.3 In addition, unlike in the case of PCa, in BPH, PAGE4 protein 
is predominantly expressed in the stromal and smooth muscle cells.3,5 
Considered together, the extensive spatiotemporal and cell‑type 
specific expression data in the fetal and diseased gland suggest that 
PAGE4 appears to play important roles in both benign symptomatic 
BPH and malignant disease of the prostate perhaps by modulating the 
effects of inflammatory stress. The fact that PAGE4 is upregulated in 
PCa precursor lesions affected by inflammatory stress lends further 
credence to this argument. Indeed, inflammation appears to play an 
important role in both BPH3,24–26 and PCa.27,28 Current epidemiological 
data indicate that over  25% of all cancers are related to chronic 
infections and other types of unresolved inflammation27 and chronic 
inflammation is now regarded as an “enabling characteristic” of all 
human cancers including PCa.28
Consistent with its role as a stress‑response protein, PAGE4 is 
upregulated in response to a variety of stress inducers including 
inflammatory stress. Thus, exposing PCa cells to environmental 
(drug treatment) or nutrient stress (glucose deprivation), or treating 
them with the proinflammatory cytokine tumor necrosis factor 
alpha (TNF‑α), results in upregulation of PAGE4 both at the mRNA 
and protein level.1 Perhaps the most tantalizing evidence supporting 
PAGE4 as a molecular link between stress and PCa onset comes from 
the observation that PAGE4 is upregulated in normal prostate epithelial 
cells (PrEC) when exposed to the same stress inducers.1
PAGE4 suppresses ROS production and protects DNA from damage
Additional evidence supporting its stress‑response function stems from 
the fact that in cells overexpressing PAGE4, levels of the CDK inhibitor 
p21 that serves as a checkpoint protein involved in DNA damage 
response were increased compared to control cells.1 The increase 
was pronounced when cells were subjected to glucose deprivation 
or Adriamycin treatment although it was not dependent on p53 
activation. Furthermore, the DNA damage response marker γ‑H2A.X 
was less activated by the stress stimulants in those cells overexpressing 
PAGE4, underscoring the protective function of PAGE4. On the other 
hand, the activation of the cell survival‑related signaling molecule 
phospho‑Akt  (pAkt) was higher in the PAGE4 overexpressing cells 
than nonexpressing control cells, indicating that PAGE4 overexpression 
attenuated the stress‑induced damage and enhanced cell survival. 
However, when these cells were treated with the highly reactive 
oxygen species  (ROS), hydrogen peroxide, the protective effects of 
PAGE4 overexpression were diminished. This suggests that PAGE4 
overexpression is insufficient to inhibit ROS‑induced cellular stress 
once ROS is generated. Finally, cells overexpressing PAGE4 showed an 
inverse correlation between PAGE4 expression and ROS levels when 
cultured in medium without glucose supplement. Treating cells with 
Adriamycin readily induced ROS while this process was inhibited by 
PAGE4 overexpression.1 All together, these results strongly suggest 
that one of the mechanisms by which PAGE4 protects stress‑induced 
cellular damage is by inhibiting ROS generation.
PAGE4 translocates to mitochondria upon stress stimulation
PAGE4 has been shown to be a predominantly cytoplasmic protein 
in prostatic tissue samples as well as in the cell lines that overexpress 
PAGE4.1,5,7,8 In light of the importance of mitochondria in ROS 
production and the cellular response to stress, it is imperative to 
discern whether PAGE4 expression in the cytoplasm is related to 
mitochondrial function. Thus, Zeng et al. interrogated mitochondrial 
fractions isolated from CWR22rv1 PCa cells grown with or without 
glucose supplement for the presence of PAGE4 by immunoblotting. 
Interestingly, the authors found that ectopically expressed PAGE4 was 
detected in the mitochondrial fraction although its expression level 
remained high in the cytosol fraction. More importantly, however, 
when the cells were cultured in medium without glucose supplement, 
increased PAGE4 protein was detectable in the mitochondrial fraction 
with a concomitant decrease in the cytosolic fraction. Consistent with 
subcellular fractionation results, confocal microscopy revealed that 
the PAGE4 protein accumulated in the mitochondria when cells were 
subjected to glucose deprivation, indicating that PAGE4 translocates 
to the mitochondria in response to stress.1
When considered together, these observations on the biology of 
PAGE4 indicate that it may represent the first molecular link between 
stress, especially inflammatory stress, and PCa. The results also suggest 
that attenuating the stress‑response pathway by targeting PAGE4 may 
be a rational approach to treat PCa. However, additional research 
will be needed to warrant this strategy. For example, direct evidence 
linking PAGE4 phosphorylation by HIPK1 in response to stress is 
lacking. Further, how phosphorylation of PAGE4 affects its intracellular 
trafficking and subcellular localization is unclear. While bioinformatics 
predicts a nuclear localization signal supporting its transcriptional 
regulatory role,9 how PAGE4 associates with the mitochondrion in 
response to stress and whether it interacts with the membrane by being 
translocated into the matrix or residing in the intermembrane space is 
not known. The availability of information regarding the expression of 
PAGE4 in various prostate cell lines9 should greatly aid in designing 
experiments to elucidate further the biology of PAGE4.
THE BIOCHEMISTRY OF PAGE4
PAGE4 is a highly intrinsically disordered protein
Despite the data implicating PAGE4 and the dynamic expression 
patterns that parallel the proliferative growth of the prostate gland 
during development and disease, the function(s) of PAGE4 remained 
poorly understood until recently. The first clue regarding its potential 
function came from examining the amino acid sequence of the PAGE4 
polypeptide. Intriguingly, while the sequence is enriched in polar and 
charged amino acids (~53%), there are few bulky hydrophobic residues 
such as L, M, F, W, and Y (<10%), suggesting that PAGE4 may be an 
IDP. Indeed, bioinformatics algorithms predicted strongly that PAGE4 
is highly intrinsically disordered.9 In agreement with these predictions, 
biochemical experiments such as denaturing sodium dodecyl 
sulfate‑polyacrylamide gel electrophoresis (SDS‑PAGE) and analytical 
size exclusion chromatography revealed that PAGE4 polypeptide 
behaved anomalously, which is typical of IDPs. In SDS‑PAGE, their 
mobility appears to be retarded because of abnormally low SDS 
binding to hydrophilic residues. In size exclusion columns, IDPs elute 
at retention times corresponding to higher molecular weight globular 
proteins due to their larger Stokes radius. Circular dichroism (CD) 
and one‑dimensional 1H Nuclear Magnetic Resonance  (NMR) 
spectroscopy over a range of temperatures (5–25°C) further confirmed 
that PAGE4 is an IDP.9 The CD spectra showed that the PAGE4 
polypeptide chain contains no significant α‑helical or β‑strand 
secondary structural elements over this temperature range as evidenced 
by low ellipticity values in the 215–230  nm region. NMR spectra 
displayed a narrow chemical shift dispersion of amide proton signals, 
with most resonances in the 7.0–8.5 ppm range. Narrow dispersion of 
peaks was also present in the aliphatic methyl region of the spectrum. 
Resonances in the amide and methyl regions of folded proteins are more 
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spread out due to ordered packing and hydrogen bonding effects. Thus, 
the lack of signal dispersion was strongly indicative of a polypeptide 
chain with little or no defined tertiary structure.9
IDPs and PIN rewiring
Comprehensive analyses of protein interaction networks  (PINs) 
from yeast to humans29 revealed that proteins that occupy hub 
positions (nodes with multiple interactions) in a PIN are significantly 
more disordered compared to proteins that constitute edges, 
highlighting the role of IDPs in signaling.30 Consistent with the 
preference for IDPs to occupy hub positions, many IDPs rapidly 
undergo disorder‑to‑order transitions upon binding to their biological 
target (coupled folding and binding) to perform their function.31 Thus, 
conformational dynamics is believed to represent a major functional 
advantage for the IDPs, enabling them to interact with a broad range 
of biological targets under normal physiological conditions where their 
expression is tightly regulated.32,33
Intrinsic disorder also appears to be an important determinant of 
dosage‑sensitive effects. Thus, IDPs are prone to initiate promiscuous 
interactions when overexpressed, suggesting that this is the likely cause 
of the resulting toxicity/pathology. Indeed, studies in model organisms 
provide compelling evidence supporting this causality.34 Interestingly, 
the same properties are strongly associated with dosage‑sensitive 
oncogenes as well as several other cancer‑associated genes,14,23 
suggesting that mass action driven molecular interactions may be a 
frequent cause of the observed pathology.35 In fact, numerous IDPs 
are also associated with several other human diseases,36,37 highlighting 
the link between intrinsic protein disorder, promiscuity, and dosage 
sensitivity.
The structural flexibility of IDPs could also contribute significantly 
to “noise” in the PINs especially when IDP expression is dysregulated. 
Indeed, recent evidence indicates that the information transduced 
in cellular signaling pathways is significantly affected by noise.38 In 
fact, it has been proposed that noise in these pathways is generated 
by the interconnected and promiscuous nature of the PINs and that 
this source of noise significantly influences the way that signals 
are transmitted. Therefore, noise may be considered as an integral 
part of the correct transmission of signals and signaling cascades. 
Mahmoudabadi et  al. recently hypothesized that noise due to IDP 
conformational dynamics can rewire PINs to cause phenotypic 
switching such as the transformation of a normal cell to a cancer cell. 
Because noise affects central regulatory switches in cell functions, it is 
plausible that alterations in noise level could rewire PIN by switching 
interacting partners by IDPs to induce pathological states such as 
cancer.39 Although this theoretical framework helps envision the role 
of IDPs in general, experimental evidence discerning noise caused 
by the conformational dynamics of PAGE4 and actually identifying 
partners that interact with it could provide much needed insight on 
the role of this IDP in PCa.
PAGE4 potentiates c‑Jun transcriptional activity
Toward this end, Rajagopalan et  al. identified the proto‑oncogene 
c‑Jun as a PAGE4 interacting partner using a yeast two‑hybrid 
system.2 Employing a cell‑based reporter system, the authors then 
went on to demonstrate that PAGE4 dramatically potentiates c‑Jun 
transactivation (Figure 3a). While these observations implied a direct 
interaction between the two proteins, evidence that indicating PAGE4 
physically interacts with c‑Jun was lacking. Thus, there remained 
the possibility that PAGE4 interacts indirectly with c‑Jun/AP‑1 
complex by binding to yet another factor in the transcription factor 
machinery assembled on the promoter. To discriminate between the 
two possibilities, Rajagopalan et al. employed single‑molecule Förster 
resonance energy transfer (smFRET) microscopy and demonstrated 
that PAGE4 binds to c‑Jun and changes conformations upon 
binding (see section on the Biophysics of PAGE4 below for details). 
Taken together, these results suggested that conformational dynamics 
may underlie the observed pleiotropic functions of PAGE4 during 
prostatic development and disease.
PAGE4 is phosphorylated at T51 in vivo and this is critical for its 
transcriptional activity
In general, across both plant and animal kingdoms, IDPs appear 
to be more prone to alternative splicing and posttranslational 
modifications  (particularly phosphorylation) than are ordered 
proteins.32,40–42 Therefore, Mooney et  al. examined the possibility 
that PAGE4 is also subjected to posttranslational modification by 
phosphorylation.8 Utilizing mass spectrometry, the authors discovered 
that PAGE4 isolated from PC3 cells is phosphorylated predominantly 
at T51. To discern the functional significance of this covalent 
modification, the authors mutated T51 to an alanine residue (T51A). 
They observed that the mutant version was not phosphorylated and 
failed to potentiate c‑Jun transactivation in a cell‑based reporter 
assay, indicating that phosphorylation at T51 is critical for this 
process8 (Figure 3b). To rule out the possibility that the mutant protein 
is not expressed or is unstable, the cell lysates are probed with the 
PAGE4 antibody in an immunoblotting experiment. These experiments 
confirmed that the T51A mutant is indeed expressed and to the same 
extent as the “wild‑type” (WT) (nonphosphorylated) PAGE4 but that 
the mutant protein is not phosphorylated by the kinase that robustly 
phosphorylates the WT PAGE4 polypeptide (Figure 3b).8
HIPK1 phosphorylates PAGE4 in vitro primarily at T51
To identify the kinase that phosphorylates PAGE4 in PCa cells, a panel of 
190 serine and threonine (S/T) kinases was surveyed by Mooney et al.8 
Homeodomain‑interacting Protein Kinase 1  (HIPK1), a component 
of the cell’s stress‑response pathway, was identified as a kinase that 
phosphorylates PAGE4 in vitro. Phosphorylation of bacterially produced 
recombinant PAGE4 was achieved by incubation with commercially 
available HIPK1 in the presence of 32P‑γATP. While the WT recombinant 
PAGE4 was robustly phosphorylated, the T51A mutant of PAGE4 had 
only ~10% of the phosphorylation level by comparison, indicating that 
HIPK1 phosphorylates PAGE4 primarily at T51.
Together, these and other results1 implicated PAGE4 in the 
HIPK1‑JNK1‑c‑Jun activated stress‑response pathway. The amplifying 
effect on c‑Jun transactivation suggested that PAGE4 may modulate 
the activity of AP‑1, a family of early response transcription factors 
with important roles in the control of cell growth, apoptosis, and 
stress response.43 Notably, c‑Jun is also upregulated in the developing44 
and diseased prostate45–48 while the AP‑1 complex is upregulated in 
symptomatic but not in asymptomatic BPH49 as well as in prostate 
cancer.50 These patterns are coincident with PAGE4 expression3 and 
underscore the importance of the PAGE4/c‑Jun interactions in prostatic 
development and disease.
While these data afford the first clue to the function of PAGE4 
at least in the prostate, more work is needed to fully comprehend 
its function(s). For example, PAGE4 may be subjected to additional 
posttranslational modifications that could potentially remodel the 
conformational ensemble and thus, uncover a latent function(s). 
Indeed, preliminary data indicate that PAGE4 is covalently 
modified by O‑GlcNAc‑transferase  (OGT) that adds O‑linked 
β‑N‑acetylglucosamine (O‑GlcNAc) on to S/T residues (Dr. Steven 
Mooney, personal communication). O‑GlcNAc modification is 
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encountered with nucleo‑cytoplasmic proteins involved in nutrient 
sensing51 and often competes for the same S/T residues recognized by 
kinases.52 In fact, alternative O‑GlcNAcylation/O‑Phosphorylation 
at the same residue can induce different conformations in the same 
polypeptide53 underscoring the critical role of posttranslational 
modifications in protein conformational dynamics. In light of the 
role of PAGE4 in stress‑response including nutrient stress, it may be 
important to discern the effect of this posttranslational modification 
on its function. In addition, c‑Jun (as well as its heterodimeric partners 
from the Fos family of transcription factors in the AP‑1 complex) is 
intrinsically disordered and subjected to phosphorylation by JNK1 
and other kinases.54,55 Therefore, how these modifications affect its 
interaction with nonphosphorylated PAGE4 and how phosphorylated 
PAGE4 interacts with the AP‑1 complex remain poorly understood.
THE BIOPHYSICS OF PAGE4
Single‑molecule fluorescence resonance energy transfer  (smFRET) 
microscopy
Rajagopalan et al. employed smFRET microscopy, a powerful technique 
used to measure distances at the 1–10 nm scale in single molecules, to 
demonstrate a direct interaction between nonphosphorylated PAGE4 
and c‑Jun.2 A unique advantage of smFRET is that it can capture 
information normally lost through ensemble averaging of heterogeneous 
and dynamic samples. Furthermore, immobilization of single molecules 
under conditions that retain their biological activity allows for extended 
observation of the same molecule for tens of seconds, facilitating the 
capture of slow conformational transitions or protein binding and 
unbinding cycles. Finally, the technique permits direct observation of 
the response to changing solution conditions or adding ligands.56
Figure 3: PAGE4 is a powerful potentiator of c‑Jun and phosphorylation of 
PAGE4 is critical for its activity. (a) PAGE4 potentiates c‑Jun transcriptional 
activity in a cell‑based assay. Luciferase is used as the reporter. MEKK 
represents MAP kinase. (b) PAGE4/c‑Jun transactivation requires T51.Top 
panel, luciferase assay of nV5‑PAGE4 WT/T51A with GAL4‑c‑Jun1−231 in 
PC3 cells. Lower panel shows a representative V5‑PAGE4 western blot of the 
respective wells in the luciferase assay. FRET from phosphorylated PAGE4 
is minimally altered by exposure to c‑Jun. (c) Cartoon showing how single 
PAGE4 molecules were tethered directly to a surface bound antibody to the 
6His tag. Gaussian fits of the FRET histograms show c‑Jun causes larger 
FRET changes in nonphosphorylated PAGE4 than kinase‑treated PAGE4. 
Details of the fits are as follows. For the A18C nonphosphorylated (d) without 
c‑Jun, FRET = 0.56 (width 0.15), and with c‑Jun, 65% molecules are 
FRET = 0.56 (width 0.15) while 35% are FRET = 0.72 (width 0.12). For 
A18C kinase‑treated PAGE4 (e), without c‑Jun, 58% have FRET = 0.56 (width 
0.15), while 42% have FRET = 0.72 (width 0.13), whereas with c‑Jun, fits 
used only single peak of FRET = 0.61 (width 0.16). FRET was 0.69 (width 
0.16) for P102C PAGE4 nonphosphorylated (f) without c‑Jun but dramatically 
changed to a double Gaussian with 70% having FRET 0.37 (width 0.16) and 
30% having FRET 0.69 (width 0.16) when c‑Jun was added. Kinase‑treated 
P102C PAGE4 (g) samples were dominated by a FRET population >80% at 
FRET 0.71 (width 0.15) both with and without c‑Jun. Data presented are 
reproduced with permission from original publications by the authors.
d
c g
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f
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Figure 2: PAGE4 expression stem cells and the effect of silencing and 
overexpression. (a) PAGE4 mRNA is upregulated in transcription factor‑induced 
pluripotent stem cells (iPS cells) compared to the parental somatic cells. The 
various somatic cells used are indicated in red bars and the resulting iPS 
cells in green bars. Data were obtained from GEO (http://www.ncbi.nlm.nih.
gov/geo/tools/profileGraph.cgi?ID = GDS3842:15390). (b) Silencing PAGE4 
expression inhibits cell survival and enhances chemocytotoxicity in prostate 
cancer cells. Prostate cancer LNCaP cells were transfected with 50 nmol l−1 
PAGE4 SMARTpool siRNA. Cell viability was evaluated by WST‑1 assay 
3–7 days after transfection. (c) Overexpression of PAGE4 protected cells from 
stress‑induced death. Prostate cancer CWR22rv1 cells were seeded in 6‑well 
plates and transfected with 4 μg of pCMV6‑PAGE4‑GFP vector (black bar) or 
empty vector pCMV6‑GFP (white bar). The number of living cells was counted 
using a hemocytometer after excluding dead cells by trypan blue staining 
1–5 days after transfection. Data presented in b and c are reproduced with 
permission from original publications by the authors.
b
a
c
WT PAGE4 interacts with c‑Jun
To discern whether or not PAGE4 physically interacts with c‑Jun, 
Rajagopalan et al.2 generated two different cysteine  (Cys) mutants of 
PAGE4 that were labeled with donor and acceptor fluorophores. Cysteine 
residues were introduced in the N‑ or C‑terminus of the 102 residue 
PAGE4 molecule at positions 18 or 102 by replacing an alanine (A18C 
construct) or proline  (P102C construct) residue by site‑directed 
mutagenesis, respectively. These mutants alternately combined with 
the single native Cys residue at position 63 in the PAGE4 polypeptide 
to generate two double mutant constructs that could be used to 
simultaneously label with fluorescent dye resulting in random attachment 
of donor and acceptor on the cysteines. The constructs were used to 
express recombinant proteins in E. coli, which were purified and labeled 
with Alexa Fluor 555 (FRET donor) and Alexa Fluor 647 (FRET acceptor). 
The labeled proteins were separated from excess unincorporated dye by 
size exclusion chromatography, and then liposome encapsulated together 
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with unlabeled recombinant c‑Jun (residues 1–241). Using this technique, 
the authors showed that a) nonphosphorylated WT PAGE4 binds to c‑Jun 
and b) upon binding to c‑Jun, PAGE4 changes conformation.
Phosphorylation of PAGE4 changes the interaction with c‑Jun
To examine the effect of phosphorylation on the conformational 
dynamics of PAGE4, recombinant PAGE4 coexpressed with HIPK1 
was purified and used in smFRET experiments.8 FRET efficiency 
measured from purified PAGE4 A18C encapsulated inside liposomes 
that were surface immobilized was increased, which suggested that 
phosphorylation causes compaction of the N‑terminal region of 
PAGE4. In contrast, essentially no change in FRET was observed in 
the C‑terminal pair of labels in PAGE4 P102C due to phosphorylation.
Direct immobilization of 6‑His tagged PAGE4 on a surface coated 
with 6‑His antibodies allowed c‑Jun to be added to the solution 
around the protein and possible conformational changes to be 
observed (Figure 3c). Without kinase exposure, FRET from PAGE4 
A18C increased from 0.56 to 0.72 upon exposure to full‑length c‑Jun 
while FRET from PAGE4 P102C decreased from 0.69 to 0.37 in the 
same conditions. The A18C PAGE4 protein was not well suited for 
testing the interaction of c‑Jun with kinase exposed PAGE4 because 
individually, both A18C and P102C mutant proteins caused similar 
shifts in FRET compared to the wild‑type protein. Therefore, the 
authors used P102C‑PAGE4 protein to determine the interaction 
between c‑Jun and PAGE4. When exposed to c‑Jun, only 17% of 
kinase‑coexpressed P102C PAGE4 had low FRET efficiency similar 
in value to that of c‑Jun interacting with nonphosphorylated PAGE4. 
In comparison, 70% of the population of nonphosphorylated P102C 
PAGE4 shifted to low FRET upon exposure to c‑Jun (Figure 3d–3g). 
Thus, the absence of the large change in FRET for the C‑terminal 
PAGE4 fluorophore pair suggested either that phosphorylation weakens 
the ability of PAGE4 to interact with c‑Jun or that if it binds c‑Jun, the 
induced conformational changes were substantially different from those 
in the case of nonphosphorylated PAGE4.8 Regardless, the smFRET 
experiments pointed to a conformational switching mechanism upon 
phosphorylation of PAGE4.
NMR spectroscopy
The structurally and dynamically heterogeneous nature of IDPs makes 
NMR spectroscopy an ideal tool for their characterization at high 
resolution. Therefore, to elucidate how phosphorylation perturbs the 
structural features of PAGE4 and to provide a possible explanation 
for the attenuation in binding to c‑Jun at the single‑residue level, He 
et al.13 employed multidimensional NMR spectroscopy.
PAGE4 becomes more compact upon phosphorylation at T51
The authors first carried out the backbone and side chain assignments 
for PAGE4. Although PAGE4 is an IDP, NMR analyses using 
chemical shifts, Nuclear Overhauser Enhancement (NOE), coupling 
constants, paramagnetic relaxation enhancement  (PRE), and 
dynamics  (heteronuclear NOE, R1, R2, R1r) data revealed that 
regions of the polypeptide chain have distinct local‑ and long‑range 
conformational preferences. These preferences were perturbed by 
phosphorylation at T51, which increases the population of transient 
turn‑like structures in the central acidic region. The central region 
thus becomes more compact and more negatively charged upon 
phosphorylation, resulting in increased long‑range contacts to basic 
sequence motifs near the N‑ and C‑termini of the PAGE4 polypeptide 
chain as determined by PRE measurements. Dynamics data indicated 
that chain flexibility is decreased in T51 phosphorylated PAGE4 relative 
to WT‑PAGE4, particularly in the central and N‑terminal regions.
Based on these results, He et al.13 used a set of conservative PRE 
and NOE restraints as inputs for calculating ensemble conformations 
for both WT‑PAGE4 and phosphorylated PAGE4. The resulting models 
provide a useful framework for visualizing preferred states of the highly 
flexible ensemble. The WT‑PAGE4 on average populate conformations 
where the highly basic N‑terminal motif  (RVRSRSRGR) is within 
20 Å of the central acidic region (E44, E47, E49, E55, E56, E60, and 
D62) neighboring C63. Phosphorylation at T51 increases the negative 
charge in this central acidic region and induces turn‑like structures 
that provide a more compact transient interaction with the N‑terminal 
motif  (Figure 4a–4d). Secondary phosphorylation at S9 lowers the 
net positive charge of the N‑terminal basic motif, and this leads to a 
weakening of the PRE effect. The interaction between these two regions 
therefore appears to be driven mostly by favorable electrostatic effects. 
In addition, other interactions between C63 and a C‑terminal motif 
centered on residue N88 contribute to the overall conformational 
ensemble. These long‑range contacts may also be at least partly due to 
electrostatic interactions of several basic residues in this region (K82, 
K84, K90, K93, and K95) with the central acidic amino acids. However, 
phosphorylation at T51 does not appear to affect this interaction as 
much as the N‑terminal motif as judged both by changes in PRE and 
dynamics data, consistent with the smFRET results by Mooney et al.8
Functional studies
NMR‑based ligand binding experiments were used to define the 
PAGE4 binding interface with human c‑Jun.13 A series of unlabeled 
c‑Jun fragments, 1–61, 1–90, 1–150, 1–223, and full‑length c‑Jun, were 
tested individually with 15N‑labeled WT‑PAGE4 and phospho‑PAGE4. 
Chemical shift perturbation experiments with the shorter c‑Jun 
fragments, 1–61, 1–90, and 1–150, showed no change in 2D 15N HSQC 
spectra of WT‑PAGE4 with up to 6 equivalents of c‑Jun fragment 
added. In contrast, addition of either unlabeled full‑length c‑Jun 
or c‑Jun  (1–223) perturbed a specific set of WT‑PAGE4 residues 
in a similar way albeit weakly. The largest chemical shift changes 
occurred in the transient helix region of PAGE4 from residues 69 to 
73 (Figure 5a–5c). The binding interaction between WT‑PAGE4 and 
c‑Jun was estimated at a KD of >50 μmol l−1 from the NMR titration 
data, with precipitation of c‑Jun at higher concentrations preventing 
a more accurate determination. Phosphorylation of PAGE4 on T51 
significantly attenuates binding at the helical interface with c‑Jun, 
consistent with lower resolution studies using smFRET (18).8
Since the c‑Jun  (1–223) fragment, but not shorter constructs, 
gave similar NMR results to full‑length c‑Jun, residues, He et  al. 
surmised that 150–223 must be important for the interaction with 
PAGE4. This region is adjacent to the basic DNA‑binding domain of 
c‑Jun, which extends from residues 257 to 276. Consistent with the 
NMR binding data, results from a luciferase assay in the PC3 prostate 
cancer cell line with truncated c‑Jun fragments demonstrated that 
PAGE4‑mediated amplification of c‑Jun transactivation was negligible 
and required inclusion of the region from 150 to 223. An additional 
mutant of PAGE4, lacking most of the N‑terminal basic motif from 
residues 5 to 11, had a small  (~3‑fold) but significant increase in 
c‑Jun transactivation. The N‑terminal motif therefore appears to have 
a partial auto‑inhibitory effect on the cellular function of PAGE4, 
possibly through its long‑range interactions with the central region.13
ALTERNATIVE SPLICING
According to AceView,57 the PAGE4 gene contains 4 exons, and RNAseq 
experiments have identified PAGE4 transcripts that could code for 
PAGE4 isoforms having 102 amino acids, which corresponds to the 
Asian Journal of Andrology 
PAGE4 and prostate cancer 
P Kulkarni et al
701
full‑length protein, as well as additional mRNAs that likely arose from 
alternative splicing (AS) encoding isoforms with 93, 44, and 43 amino 
acids (for PAGE4’s AceView entry, see www.ncbi.nlm.nih.gov/gene/9506). 
However, so far, to the best of our knowledge, there is no experimental 
evidence demonstrating the existence of PAGE4 isoforms resulting from 
AS. However, as discussed below, there are several reasons for making 
efforts to determine whether the indicated AS isoforms or other PAGE4 
AS isoforms do indeed exist, and if so, to determine the functions of these 
AS isoforms and whether they contribute to the development of PCa.
In general, increasing amounts of AS isoforms are associated with 
increasing organism complexity, suggesting that AS isoforms likely 
play important roles in the development of complexity among the 
multicellular eukaryotes.58 Also, using deep sequencing to estimate AS 
complexity suggests that approximately 95% of human multiexon genes 
undergo alternative splicing,59 but it is unclear what fraction of these AS 
events actually leads to different protein isoforms, so this point needs 
to be tested experimentally for each different and potentially important 
RNA transcript indicated to exist by RNAseq or EST experiments.
At the protein translation level, pre‑mRNA segments that are 
observed to undergo AS are found to code for IDP regions much 
more often than for structured regions and these AS‑determined IDP 
regions often contain sites for binding to nucleic acids or to other 
proteins, so these AS events often lead to the “rewiring” of the networks 
involving genes or protein‑protein interactions.60,61 Interestingly, 
studies of tissue‑specific AS indicate that this rewiring or remodeling 
of protein‑protein interaction networks is likely an important factor 
leading to different functional pathways in different types of cells,62–64 
which in turn is important for the different biochemistry that occurs 
in the different types of cells in multicellular organisms.61
Figure 4: A model for phosphorylation‑induced conformational ensemble switching seen in PAGE4. (a) The nonphosphorylated PAGE4 adopts preferred 
transient structures such as the one highlighted from an ensemble of the 20 lowest energy conformers, where, on average, the N‑terminal basic motif (blue 
spheres: Arg‑4, Arg‑6, Arg‑8, Arg‑10, and Arg‑12) interacts weakly with the central acidic region (red spheres: Glu‑43, Glu‑47, Glu‑49, Glu‑55, Glu‑56, 
Glu‑60, and Asp‑62) neighboring Thr‑51 (yellow). (b) Upon phosphorylation at Thr‑51, the central region becomes more compact and more negatively 
charged, decreasing the average distance between Thr(P)‑51, the basic motif, and the transient helix (magenta). (c and d) Models of the transient interaction 
between the central acidic region and the C‑terminal basic motif (blue spheres; Lys‑82, Lys‑84, Lys‑90, Lys‑93, and Lys‑95) in nonphosphorylated PAGE4 (c) 
and Thr(P)‑51 PAGE4 (d). The total number of distance restraints used was as follows: (a) 51; (b) 55; (c) 53; (d) 61. Data presented are reproduced with 
permission from original publications by the authors.
dc
ba
Figure 5: Summary of PAGE4 functional studies. (a) Regions from 
two‑dimensional 1H‑15N HSQC spectra in the titration of 15N‑labeled WT 
PAGE4 with unlabeled c‑Jun showing superimposed control (black), 1:1.5 
PAGE4/c‑Jun (red), and 1:3 PAGE4/c‑Jun (green) spectra. (b) Similar regions 
using 15N‑labeled Thr(P)‑51 PAGE4 with unlabeled c‑Jun at the same molar 
ratios as for a. (c) Chemical shift perturbation plot for WTPAGE4 (blue) and 
Thr(P)‑51 PAGE4 (red) as a function of residue number. Values of dDtotal 
below the dashed line are estimated to be within the experimental error for 
measuring chemical shift changes. Arrows and cylinders represent regions 
with transient β‑strand and α‑helical preferences, respectively. The red star 
indicates the position of phosphorylation. Data presented are reproduced with 
permission from original publications by the authors.
b
a
c
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Although this manuscript deals with PAGE4 and the functional 
alterations that arise from phosphorylation, which is a particularly 
important type of posttranslational modification (PTM), we would like 
to point out that for other important proteins, such as p53,65 Bcl‑2,66 
and many others,61 their biological impact arises from functional IDP 
regions that are modulated in their activities by both AS and PTMs. 
Furthermore, bioinformatics studies have suggested that proteins 
involved with cellular differentiation are especially enriched in IDP 
regions.67 Combining these observations has led to the proposal that 
synergy among IDP, PTM, and AS was crucial for both the evolution of 
multicellular organisms61 and thus also for the gene regulatory networks 
that underlie the development of complex multicellular organisms.68 
For these reasons, we believe that it would be worthwhile to investigate 
whether PAGE4 contains isoforms that arise from AS, and if so, whether 
the modulation of PAGE4 function by PTMs  (phosphorylation or 
other modifications) and also by AS combine to contribute to the 
development of the cellular alterations that lead to cancer.
CONCLUSIONS
PAGE4 is one of the few PCa‑related IDPs, and the only CTA 
overexpressed in PCa, that has been studied in considerable detail. 
Progress in research over the last decade has uncovered this IDP as an 
important player in prostatic development and disease. The cumulative 
data suggest that PAGE4 may represent the first molecular link between 
stress and PCa. In addition, experimental evidence supports the idea 
that the pleotropic functions of PAGE4 result from its interactions 
with different partners. Such interactions appear to be facilitated by 
the conformational plasticity of the PAGE4 protein(s), which may also 
uncover novel functionalities latent in the PAGE4 ensemble expanding 
its functional utility through new binding interactions. For example, 
phosphorylation of PAGE4 leads to conformational shifts in the 
dynamic ensemble with large functional consequences. Such changes in 
the structural ensemble are similar conceptually to the conformational 
switching events seen in some marginally stable  (“metamorphic”) 
folded proteins in response to mutational or environmental triggers.69
In summary, PAGE4 is a prototypical IDP involved in PCa that 
exploits its conformational flexibility for functional gain. While questions 
remain, much progress has been made in understanding PAGE4 structure 
and molecular function. As such, PAGE4 should be given further 
consideration as a novel therapeutic target for treating and managing PCa.
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